Abstract
An open ended clinical trial of Indoramin (WY 21901), a new antihypertensive agent with both α adrenergic blocking and cardio inhibitory properties, was conducted on a group of 27 patients with mild or moderate essential hypertension. Blood pressures, erect and supine, were effectively lowered. In 70% of the patients the mean standing diastolic pressures were well controlled. Heart rate was not significantly lowered. Side effects occurred in 80% of patients, but did not persist in most of them. Severe side effects, necessitating withdrawal of Indoramin, were experienced by 1/3 of the patients. Proteinuria was observed in 3 patients and a slightly elevated serum urea in 1. No other biochemical tests were abnormal.
Original language | English |
---|---|
Pages (from-to) | 1569-1572 |
Number of pages | 4 |
Journal | South African Medical Journal |
Volume | 48 |
Issue number | 37 |
State | Published - 1974 |
Externally published | Yes |